Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 2/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.38 |
| ▸ | GABRP | O00591 | 6/20 | 0.38 |
| ▸ | GABRD | O14764 | 6/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.38 |
| ▸ | GABRE | P78334 | 6/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.38 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.38 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16471701 | 0.89 | CNR2 (0.47) | CNR2MAP3K5GABRA1GABRG2GABRB3 | |
| SCHEMBL15417914 | 0.88 | CNR2 (0.42) | CNR2TNFMAP3K5GABRA1GABRG2 | |
| SCHEMBL16471710 | 0.88 | CNR2 (0.46) | CNR2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16471711 | 0.84 | CNR2 (0.43) | CNR2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16471709 | 0.77 | CNR2 (0.47) | CNR2TNFMAP3K5GABRA1GABRG2 | |
| SCHEMBL15417944 | 0.76 | REN (0.44) | CNR2MAP3K5GABRA1GABRG2GABRB3 | |
| SCHEMBL15417884 | 0.76 | CNR2 (0.43) | CNR2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2297064 | 0.75 | MAP3K5 (0.54) | MAP3K5GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2946990 | 0.73 | GABRA1 (0.46) | CNR2MAP3K5GABRA1GABRG2GABRB3 | |
| SCHEMBL16471704 | 0.73 | CNR2 (0.36) | CNR2ALDH1A1SMN1; SMN2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556159-B2 | Renin inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-31 | — | — | US | disclosed |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-9278944-B2 | Nitrogen-containing saturated heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-08-20 | — | — | US | disclosed |
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011807-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | CNR2 185/4885TNF 4744/4885MAP3K5 1098/4885 |
| US-20150232459-A1 | NOVEL RENIN INHIBITOR | REN, AGTR1, ACE | CNR2 321/4885TNF 4805/4885MAP3K5 698/4885 |
| US-20160145220-A1 | NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | REN, AGTR1, AGTR2 | CNR2 185/4885TNF 4744/4885MAP3K5 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.